Kimberlee C. Drapkin - Jan 9, 2023 Form 4 Insider Report for Jounce Therapeutics, Inc. (JNCE)

Signature
/s/ Caroline Gammill, Attorney-in-fact
Stock symbol
JNCE
Transactions as of
Jan 9, 2023
Transactions value $
-$15,661
Form type
4
Date filed
1/11/2023, 07:30 PM
Previous filing
Jun 17, 2022
Next filing
May 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Sale -$6.95K -6.32K -7.88% $1.10 73.8K Jan 9, 2023 Direct F1, F2
transaction JNCE Common Stock Sale -$8.71K -7.78K -10.54% $1.12 66K Jan 10, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
F2 Represents the weighted average share price of an aggregate total of 6,315 shares sold in the price range of $1.03 to $1.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 7,781 shares sold in the price range of $1.05 to $1.15 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

Exhibit 24 - Power of Attorney